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Summary 
 
 
 
 
1-(4-Fluorophenyl)propan-2-amine (4-fluoroamphetamine, 4-FA) is a psychomotor stimulant that 
was first synthesized in the early 1940s. The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) received the first formal notification of the detection of 4-FA in Europe in 
December 2008 although its presence has been noted since at least 2007. In Europe, it has been 
found in tablets sold as ‘ecstasy’/MDMA, paste or powder sold as amphetamine. In addition, it can 
be obtained from Internet retailers as a ‘research chemical’ and it has also been detected as an 
adulterant present in other illicit controlled substances. 4-FA appears to be most commonly 
administered orally or by nasal insufflation (snorting). The EMCDDA has been notified of 
seizures from various locations in Europe since 2008. 
 
Data indicate that 4-FA may be able to inhibit monoamine oxidase and that it functions as a 
substrate-type releasing agent of dopamine, norepinephrine and serotonin. It has been shown to 
display amphetamine-like features in vivo and in vitro and further research is warranted to 
investigate the extent to which 4-FA displays a potential for abuse and dependence in both animals 
in humans that is comparable to substances such as amphetamine, cocaine or related 
psychostimulants. Case report data in the scientific literature that unambiguously confirm a causal 
relationship between adverse effects of 4-FA and its presence in biofluids are limited to only a 
relatively small number of cases. In cases where this information is available, reported clinical 
features were associated with those of a sympathomimetic toxidrome. The EMCDDA has received 
reports from positive identifications in biofluids samples from 2009 onward. It has been reported 
that 4-FA might have established itself as a drug of choice in a surveyed convenience sample of 
249 life-time users of 4-FA in one European country. Surveys that systematically assess the 
prevalence of use 4-FA within the general population are not available.   
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1.   Substance identification  
A. International Nonproprietary Name (INN) 
None 
B. Chemical Abstract Service (CAS) Registry Number 
459-02-9 (free base) 
64609-06-9 (hydrochloride salt) 
72522-20-4 ((αR)-free base) 
788123-23-9 ((αS)-free base) 
127515-13-3 ((αS)- hydrochloride salt) 
72522-24-8 ((αR)- hydrochloride salt) 
1419922-92-1 (1,2,3,4,5,6-
13
C6-free base) 
59963-24-5 (D-mannopyranose, 1-(hydrogen sulfate)) 
153506-17-3 (4-(fluoro-
18
F)) 
72522-20-4 (L-leucine, N-acetyl- compd. with (αR)-4-fluoro-α-
methylbenzeneethanamine, 1:1) 
788123-23-9 (L-leucine, N-acetyl- compd. with (αS)-4-fluoro-α-
methylbenzeneethanamine, 1:1) 
1782279-11-1 (d5-hydrochloride salt) 
1783027-85-9 (d5-free base) 
C. Other Names 
1-(4-Fluorophenyl)-2-propanamine, 1-(p-fluorophenyl)-2-aminopropane, 2-amino-
1-(4'-fluorophenyl)propane, 2-amino-1-(4'-fluorophenyl)propane, 2-amino-1-(p-
fluorophenyl)propane, 2-amino-1-(para-fluorophenyl)propane, p-fluoro-α-
methylphenethylamine, 2-(4-fluorophenyl)-1-methylethylamine, 2-(4-fluoro-
phenyl)-1-methyl-ethylamine, α-methyl-β-(4-fluorophenyl)ethylamine, α-methyl-β-
(p-fluorophenyl)ethylamine, α-methyl-p-fluorophenethylamine, 1-(4-
fluorophenyl)prop-2-ylamine, 1-(4-fluorophenyl)-2-propylamine, 1-(4-
fluorobenzyl)ethylamine, 1-p-fluorophenyl-2-propylamine, p-fluoro-α-methyl-
phenethylamine, para-fluoro-α-methyl-phenethylamine, 4-fluoro-α-methyl-
phenethylamine, 4-fluoroamphetamine, p-fluoroamphetamine, 
parafluoroamphetamine, PFA, 4-F-A, PAL-303, p-FA, P-FMP, 4-FMP, 4FMP, 4-
FA. 
D. Trade Names 
None 
E. Street Names 
Flux, Fifa. 
 
F. Physical properties 
4-FA HCl is a white crystalline powder. 
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G. WHO Review History 
4-FA was not previously pre-reviewed or critically reviewed. 
 
2. Chemistry 
A. Chemical Name 
IUPAC Name: 1-(4-Fluorophenyl)propan-2-amine 
CA Index Name: 4-Fluoro-α-methyl-benzeneethanamine 
 
B. Chemical Structure 
Free base: 
 
Note: Asterisk (*) refers to a chiral centre 
 
Molecular Formula: C9H12FN (free base) 
Molecular Weight: 153.20 g/mol 
Melting point: 
Hydrochloride salt: 156–157 °C (dry acetone)1 
Hydrochloride salt: 152–154 °C2 
Hydrochloride salt: 152–154 °C3 
Hydrochloride salt: 152–154 °C4 
(αS)-Hydrochloride salt: 195–198 °C2 
(αR)-Hydrochloride salt: 195–197 °C2 
Boiling point:  
Free base: 95–96 °C (17 mmHg)1 
Free base: 78 °C (10 mmHg)
2
 
Free base: 96 °C (19.5 mmHg)
4
 
Free base: 90 °C
3
 
 
C. Stereoisomers 
The presence of a chiral center at the α-carbon of the side chain gives rise to the 
enantiomeric pair of (S)-4-FA and (R)-4-FA, respectively. However, 4-FA is most 
likely to be available as the racemic mixture. 
 
D. Synthesis 
Methods of manufacturing: 
4-FA may be obtained from a variety of synthetic methods that are commonly 
employed for the preparation of amphetamine (e.g.
5
). A classic approach might 
include the use of the 1-(4-fluorophenyl)propan-2-one (4-fluorobenzyl methyl 
ketone) (a) and exposure to reductive conditions (i) (e.g. using formamide
1
) to give 
NH2
CH3
*
F
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racemic 4-FA (b). Depending on the availability of starting materials, precursor (a) 
may be obtained from a variety of synthetic procedures. Another common approach 
includes the reduction of the nitroalkene intermediate 1-fluoro-4-(2-nitroprop-1-en-
1-yl)benzene
2,6-9
 (c) where 4-fluorobenzaldehyde may serve as the starting material. 
Enantiomerically pure forms of 4-FA have been prepared with the help of 
enzymes
8, 10-14
 and a number of chemical methods have also been reported.
2, 9, 15-17
 
Alternative suggestions for the preparation of 4-FA have been published.
3, 4
 The 
EMCDDA received information in 2009 about some 4-FA samples analyzed by the 
Forensic Science Service. The presence of specific impurities were associated with 
the Leuckart synthesis, which pointed to the possible use of 4-fluorobenzyl methyl 
ketone) (a) as the starting material.
18
 
 
 
E. Chemical description. 
4-FA is a ring-substituted analog of amphetamine. Amphetamine is listed in 
Schedule II of the United Nations 1971 Convention on Psychotropic Substances. 
The N-methyl derivative methamphetamine is listed in the same Schedule. 
F. Chemical properties 
4-FA hydrochloride is as a crystalline solid and soluble in ethanol, DMSO and 
dimethyl formamide (DMF). The solubility of 4-FA hydrochloride in ethanol is 
given as approximately 20 mg/mL and approximately 30 mg/mL in DMSO and 
DMF, and approximately 10 mg/mL in phosphate-buffered saline (PBS, pH 7.2).
19
 
G. Chemical identification 
The first melting point was described in the early 1940s followed by several 
examples in later years (Section B). More detailed analytical were published in 
1992 and included thermal investigations into the nature of polymorphism,
20
 
NMR
21
 and crystal structure analysis.
22
 The first comprehensive characterization of 
4-FA and related isomers and derivatives was reported in 2005.
23
 Presumptive test 
results for 4-FA using the RAL color scheme were as follows. Marquis: RAL 9003 
at 0 min and RAL 2012 at 5 min; Mecke: RAL 9003 at 0 min and RAL 1016 at 5 
min; Mandelin: RAL 1018 at 0 min and RAL 1020 at 5 min; Simon: RAL 1017 at 0 
min; Simon + catalyst: RAL 1017 at 0 min and RAL 8008 at 5 min; Scott: RAL 
3014 at 0 min and RAL 3014 at 5 min.
24
 4-FA has been employed for analytical 
purposes and featured in a range of routine methods of analysis associated with 
forensic and clinical investigations (Table 1).  
i
(a) (b)
F
O
Various routes NH2
CH3
*
F
ii
(c) (b)
F
NO2 NH2
CH3
*
F
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Table 1. Representative examples of scientific literature associated with chemical analysis and 4-fluoroamphetamine  
Techniques 
a
 Comment Reference 
Thermal methods Characterization of 4-FA HCl polymorphism. Marthi et al.
20
 
1
H-NMR Characterizations of compound including use chiral Eu-shift 
reagents. 
Podányi
21
 
XRD Characterization of crystal structure properties of compound. Simon et al.
22
 
GC-MS Metabolism study in rats following administration of para-fluoro-
deprenyl.  
Lajtha et al.
25
 
GC-MS, IR, NMR Characterization of seized compounds. Rösner et al.
23
 
GC-MS, LC, LC-MS Characterization of collected compounds. Kikura-Hanajiri et al.
26
 
LC-FL, LC-TOF-MS Characterization of collected compounds. Min et al.
27, 28
 
GC-MS, LC-DAD Characterization of collected compounds. Takahashi et al.
29
 
GC-(EI/CI)-MS(/MS) Characterization of seized compounds. Westphal et al.
30
 
LC-FL, LC-ESI-TOF-MS Characterization of collected compounds. Inagaki et al.
31
 
PS-MS, CE-MS, CZE-UV Method development. Jhang et al.
32
 
LC-TOF-MS Detection in whole blood samples related to casework.  Johansen and Hansen
33
 
Various approaches to 
ionization and MS 
Method development. Lee et al.
34
 
1
H-NMR and UV 4-FA obtained from synthesis.  Lichtenberger 
9
 
GC-MS Employment of chiral derivatization reagent. Mohr et al.
35
 
Immunoassays Evaluation of cross-reactivities to EMIT assays. Nakanishi et al.
36
 
GC-MS, LC-Q-TOF-MS, 
NMR 
Characterization of seized compounds. Reitzel et al.
37
 
Immunoanalysis, GC-MS Detection biofluids. Röhrich et al.
38
 
LC-Q-trap-MS/MS Detection in hair samples. Rust et al.
39
 
LC-TOF-MS Characterization of collected compounds. Shanks et al.
40
 
UHPLC-QqQ-MS/MS Detection in oral fluid. Strano-Rossi et al.
41
 
PTR-MS Method development.  Sulzer et al.
42
 
LC-QqQ-MS/MS Detection in authentic urine samples. Al-Saffar et al.
43
 
CE-LIF, CE-UV, MEKC-
UV, LC-Q-TOF-MS 
Method development for saliva analysis. Chen et al.
44
 
LC-QqQ-MS/MS Analyses of biofluids. Helander et al.
45
 
GC-MS Method development and application to waste water analysis. Mwenesongole  et al.
46
 
GC-MS, LC-IT-MS, NMR Synthesis and characterization of isomers. Nakazono  et al.
47
 
LC-Q-TOF-MS Method development in whole blood and application to casework. Pedersen et al.
48
 
Immunoanalysis Cross-reactivity studies. Petrie et al.
49
 
Colour spot test Method development using a spectrophotometric reagent. Philp et al.50 
LC-TOF-MS Method development and application to postmortem blood samples. Roman et al.
51
 
UPLC-QqQ-MS, LC-Q-
TOF-MS 
Method development in blood matrix for application to casework. Rosano et al.
52
 
LC-DAD, LC-Q-MS Method development and application to collected samples 
combined with in vitro pharmacology assays. 
Rosenauer et al.
53
 
GC-MS, LC-DAD, LC-Q-
TOF-MS, NMR 
Detection of seized compounds. Zuba et al.
54
 
HS-SRI-TOF-MS Method development. Acton et al.
55
 
LC-Q-TOF-MS/MS, LC-
Q-ion trap-MS/MS 
Detection in serum and urine. Al-Abri et al.
56
 
LC-DAD Method development for chiral separation.  Geryk et al.
57
 
Immunoanalysis, GC-MS Method development and chemical derivatizations.  Holler et al.
58
 
LC-Q-TOF-MS Method development for urine analysis.  Paul et al.
59
 
LC-QqQ-MS/MS Method development for hair analysis and application to authentic 
specimens. 
Strano-Rossi et al.
60
 
LC-QqQ-MS/MS Method development for urine analysis and application to authentic 
specimens. 
Tang et al.
61
 
LC-UV Chiral analysis of products obtained from Internet retailers. Taschwer et al.
62
 
LC-DAD Method development for chiral separation. Geryk et al.
63
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TLC, GC-NPD, GC-MS Identification of submitted samples. Hondebrink et  al.
64
 
LC-DAD Method development for chiral separation. Kalíková  et al.
65
 
EMIT, LC-QqQ-MS/MS Detection in serum and urine. Laskowski et al.
66
 
GC-MS, LC-QqQ-MS/MS Detection in serum. Maas et al.
67
 
LC-QqQ-MS/MS Method development in whole blood. Odoardi et al.
68
 
LC-TOF-MS Application to analyses of authentic urine samples. Sundström et al.
69
 
a 
XRD: X-ray diffraction; GC: gas chromatography; MS: mass spectrometry; IR: infrared; NMR: nuclear magnetic 
resonance spectroscopy; LC: liquid chromatography (various forms); FL: fluorescence; TOF: time-of-flight; EI: electron 
ionization; CI: chemical ionization; DAD: diode array detector; ESI: electrospray ionization; PS: paper spray; CE: capillary 
electrophoresis; CZE: capillary zone electrophoresis; Q: quadrupole; QqQ: triple quadrupole; PTR: proton-transfer-reaction; 
LIF: laser induced fluorescence; MEKC: micellar electrokinetic capillary chromatography; IT: linear ion trap; HS: head 
space; SRI: selective reagent ionization; TLC: thin-layer chromatography; NPD: nitrogen-phosphorus detector; EMIT: 
enzyme multiplied immunoassay technique. 
 
3. Ease of convertibility into controlled substances 
No information available. 
 
4. General pharmacology 
4-FA is a ring-substituted amphetamine with properties that are also encountered with 
cocaine and other amphetamine-like psychostimulants and a key feature includes the 
ability to increase extracellular levels of dopamine (DA), norepinephrine (noradrenaline, 
NE) and serotonin (5-HT), respectively. From a contextual perspective, earlier research 
involving 4-FA is related to work on substances with pressor effects (e.g. ephedrine 
derivatives), in addition to research on potential appetite suppressants (e.g. fenfluramine or 
phenmetrazine) and other substances known to interact with the monoaminergic system, 
such as L-deprenyl or 4-chloroamphetamine.   
A. Pharmacodynamics 
As summarized in Tables 2 and 3, earlier work pointed toward interactions with the 
monoaminergic system and data obtained from studies in more recent years supports the 
suggestion that 4-FA functions as a substrate-type releasing agent of DA, NE and 5-HT and 
that it displays amphetamine-like features in a number of in vivo and in vitro assays. 4-FA 
induces locomotor activity in mice and is associated with DA release in rat striatum and rat 
nucleus accumbens.
70, 71
 Drug discrimination studies performed in rats showed that 4-FA 
substituted for the 5-HT releaser fenfluramine
72
 although this was not confirmed in rats 
trained to discriminate between the 5-HT releasing agents (+)-MBDB, 5-methoxy-6-
methyl-2-aminoindan (MMAI) and saline. In this case, 4-FA fully mimicked (+)-
amphetamine instead.
70
 It has recently been shown that 4-FA differed from (+)-
amphetamine in its ability to result in higher 5-HT dialysate concentrations. These levels 
were obtained from rat nucleus accumbens and correlated with diminished motor stimulant 
activity, which provided support for the hypothesis that 5-HT release might be able to 
dampen the stimulant effects of amphetamine-type substances that are mediated by DA.
71
 
Some user reports indicate that 4-FA might show pro-social effects in humans that might 
share some overlap with MDMA.
73, 74
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Table 2. 4-FA in-vitro uptake and release data 
 
Uptake 
a 
Release 
b 
Affinity
 c 
Ref 
DAT 
IC50/µM 
NET 
IC50/µM 
SERT 
IC50/µM 
DAT  
 
NET  SERT  DAT 
Ki/µM 
NET 
Ki/µM 
SERT  
Ki/µM 
 
-- -- ID50 = 
10
 d
 
4.10%
 d
 1.16%
 d
 2.98%
 d
 -- -- -- Magyar  and 
Knoll
75
 
ID50 = 
48.7
 d
 
-- ID50 = 
10
 d
 
-- -- -- -- -- -- Magyar et al.
76
 
0.270 0.356 2.352 -- -- -- -- -- -- Marona-
Lewicka  et 
al.
70
 
-- -- -- EC50/nM 
51.5 
EC50/nM 
28.0 
EC50/nM 
939 
--
 
-- -- Wee et al.
7
 
0.77 0.42 6.8 EC50/nM 
200 
EC50/nM 
37 
EC50/nM 
730 
-- -- -- Nagai et al.
77
 
9.5 10.3 94.83 -- -- -- -- -- -- Rosenauer  et 
al.
53
 
3.7 0.2 19 Yes 
e
 Yes
 e
 Yes 
e
 11.0 13.5 32.1 Rickli et al.
78
 
Additional in-vitro data 
Receptor binding profiles 
c
: Ki (µM): 5-HT1A = 4.4; 5-HT2A = 11.3; 5-HT2C = 7.8; α1A > 4.9; α2A = 4.4; D1 
> 12; D2 > 20; D3 > 17; H1 > 13; TA1rat = 0.08; TA1mouse = 0.32; TA1human > 20; 5-HT2B receptor activation: 
EC50/µM = 11.4; activation efficacy = 49%.   
Comparison with MDMA: Ki (µM): 5-HT1A = 12.2; 5-HT2A = 5.9; 5-HT2C > 13; α1A > 6; α2A = 15; D1 > 
12; D2 = 25; D3 > 17; H1 > 13; TA1rat = 0.37; TA1mouse = 2.4; TA1human = 14.6.   
78
 
Cytotoxicity: None detected under conditions used.
 f
 
Rickli et al.
78
 
Release studies in mice using radiolabeled cardiac norepinephrine showed that 4-FA cause dose-dependent 
release. At the 10 mg/kg level, observed release following amphetamine and d-methamphetamine 
administration was comparable. 
g
 
Benington and 
Morin 
6
 
Inhibition of monoamine oxidase (MAO): 40% inhibition at 1 mM. 
h
 Beregi et al.
79
 
Inhibition of phenethanolamine N-methyltransferase studied with pI50 = 3.01; comparison with 
tranylcypromine: pI50 = 4.05 
i
  
Fuller et al.
80
 
Binding to phenylalanyl-tRNA synthetase isolated from E. coli with Ki = 0.48 mM. Santi et al. 
81
 
Investigation of MAO inhibition (MAOI) using rat brain mitochondria. I50 value for 4-FA = 16 µM 
compared to 1.9 µM for 4-chloroamphetamine. 
j
 
Fuller et al.
82
 
Study with homologous initiating and non-initiating protein synthesis systems using rabbit reticulocyte 
lysates. 4-FA and amphetamine were observed to inhibit protein synthesis and aminoacylation under the 
conditions studied.  
Nowak and 
Munro 
83
 
Investigation of MAOI using mitochondrial MAO obtained from whole rat brain homogenates. Fixed 
concentrations of 100 µM 
14
C-5-HT (MAO-A) and 
14
C-phenethylamine (MAO-B) were used as substrates. 
Ki/µM (4-FA) = 28 (MAO-A) and 240 (MAO-B), competitive inhibition. Comparison: Ki/µM 
(amphetamine) = 8.0 (MAO-A) and 475 (MAO-B).  
Fuller et al.
84
 
G-protein activation was not observed with 4-FA when using a [
35S]GTPγS binding assay.   Nonaka et al.85 
In contrast to number cathinone derivatives, 4-FA and some other amphetamines, did not react with the 
tetrazolium-based WST-1 reagent when tested in the absence of SH-SY5Y neuroblastoma cells.  
den Hollander 
et al
86
 
a
 Ref 
75
: Rat brain homogenates obtained from CFY Sprague-Dawley rats following synaptosomal preparation procedure 
published by Snyder and Coyle for uptake inhibition studies.
87
 Concentrations of [
3
H]5-HT, [
3
H]DA and [
3
H]NE were 0.1 
nmol/mL. Ref 
78
: HEK293-hDAT, HEK293-hNET, HEK293-hSERT; N-methyl-[
3
H]-nisoxetine and indatraline (NET), 
[
3
H]citalopram and indatraline (SERT), [
3
H]WIN35,428 and indatraline (DAT). Ref 
70
: whole brain minus cerebellum (male 
Sprague-Dawley rats) used for synaptosomal preparations; [
3
H]5-HT, [
3
H]DA and [
3
H]NE (10 nM). Ref 
53
: HEK293-
hSERT, HEK293-hNET and HEK293-hDAT. Cells incubated with test compounds for 5 min before the tritiated substrates 
were added to incubation buffer: 0.03 μM [3H]5 HT and 0.05 μM [3H]MPP+.  
b
 Ref 
7
: Synaptosomal preparations: rat caudate (for DA release) or whole brain minus cerebellum and caudate (for NE and 
5-HT release); [
3
H]MPP
+
 as radioligand for DA and NE release, [
3
H]5-HT for 5-HT release measurements. Ref 
78
: 100 µM 
of test compound used. HEK293-hDAT, HEK293-hNET, HEK293-hSERT ([
3
H]DA, [
3
H]NE, [
3
H]5-HT). Ref 
77
: 
Synaptosomal preparations from male Sprague-Dawley rats: striatum for DA and cortex for 5-HT and NE; re-uptake assay 
initiated by addition of [
3
H]DA (63 nM), [
3
H]5-HT (125 nM), and [
3
H]NE (125 nM); reaction mixture was incubated at 37 
°C for 5 min; for release assays: synaptosomes pre-loaded with [
3
H]DA, [
3
H]5-HT, and [
3
H]NE; release terminated after 5 
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min ([
3
H]DA) and 30 min ([
3
H]5-HT, and [
3
H]NE).  
c
 Ref 
78
: [
3
H]-8-OH-DPAT and indatraline (5-HT1A), [
3
H]ketanserin and spiperone (5-HT2A), [
3
H]mesulergine and mianserin 
(5-HT2C), [
3
H]prazosin and risperidone (α1 adrenergic receptor), [3H]rauwolscine and phentolamine (α2 adrenergic receptor), 
[
3
H]SCH 23390 and butaclamol (DAD1), [
3
H]spiperone and spiperone (DAD2 and DAD3), [
3
H]pyrilamine and clozapine (H1) 
and [
3
H]-RO5166017 and RO5166017 (TA1). 5-HT2B activation: HEK293-h5-HT2B and FLIPR assay. 
d
 Ref 
75
: release from synaptosomes (rat cerebral cortex, hypothalamus and striatum) determined as a percentage value 
relative to control following the approach published by Ferris et al.
88
  Methamphetamine values: [
3
H]5-HT (5.23%), [
3
H]DA 
(8.85%) and [
3
H]NE (4.75%).
 
e
 Ref 
78
: Monoamine release expressed as percent reduction of monoamine cell content compared with vehicle (0% = no 
release; 100% release all monoamines released from the cells). DAT: ~45%, NET: ~40%; SERT: ~50%. Essentially 
comparable with releasing activity of MDMA. 
f
 ToxiLight BioAssay (4 h, 37 °C, incubation with 100 µM test drug).  
g
 Ref  
6
: Injected DL-norepinephrine-7-
3
H retained by the heart tissue after drug treatment (tail vein injection of the male 
Swiss white mice); drugs administered subcutaneously after 1 h and mice were sacrificed after 3 h. At 10 mg/kg levels: 4-FA 
= 50%, amphetamine = 58% and d-methamphetamine = 57%. 
h
 Ref 
79: Warburg’s technique was employed using tyramine as the substrate. Incubation was for 1 h at pH 7 and 37 °C. 
i
 Ref 
80
: Enzyme source: homogenate of whole rabbit adrenals; norepinephrine (40 µM) as substrate and measurement of 
epinephrine formation; enzyme transfer of methyl group using S-adenosyl-L-methionine (SAM) as co-factor.  
j
 Ref 
82
: [
14
C]Serotonin as substrate (100 µM); incubation with enzyme) for 20 min at 37 °C.  
 
 
Table 3. 4-FA in-vivo assays
 
Behaviour Neurochemistry / physiological responses 
/ etc. 
Ref 
 
-- Toxicity studies in mice; see Section 5. In 
dogs and guinea pigs pressor activities were 
noted whereas depressing effects were 
observed in rabbits.   
Suter and Weston
1
 
 Toxicity data in mice, see Section 5; 
hypertensive effects equivalent to 
amphetamine; anorectic effects investigated 
in the rat at 5 mg/kg; locomotor effects in 
mice investigated at 10 mg/kg.
 a
 
Beregi et al.
4
 
-- Anorectic dose (mg/kg): rat = 3.5; dog = 2.
b 
Analgesia (mg/kg): mice = 10.
 b  
Anticonvulsant action (mg/kg): mice > 20.
 b  
Vasopressive action. Rat: increase at 0.25 
and 0.5 mg/kg.
 b
  
Beregi et al.
79
 
-- No significant impact on whole rat brain 
serotonin levels compared to saline.
 c 
  
Fuller et al.
89
 
Intraperitoneal administration of 5 mg/kg and 10 
mg/kg 4-FA in rats trained by the Sidman 
avoidance conditioning procedure. At the 10 
mg/kg dose, bar pressing was disrupted resulted 
in death within 6–20 h.  
-- Beaton et al.
90
 
-- Temporary reduction of whole rat brain 
serotonin and 5-hydroxyindoleacetic acid 
levels and tryptophan hydroxylase activity 
(up to 24 h) whereas 4-chloro and 4-
bromoamphetamine caused reductions for 
up to a week. 
d 
  
Fuller et al.
82
 and Gál 
91
 
-- 4-FA administration resulted in reduction 
of serotonin levels in brainstem and 
telencephalon when pre-treated with 
iprindole. No changes observed 24 h 
without pre-treatment. Two weeks later, 
reductions were observed in both tissue 
Sherman et al.
92
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extracts under both treatment conditions. 
e
 
Unpublished data were mentioned that 4-FA did 
not show effects on the central nervous system. 
Details not reported.  
Administration of 14 mg/kg (i.p.) resulted 
in a 11.1% increase of tryptophan levels in 
rat brain whereas serotonin and 5-
hydroxyindoleacetic acid levels did not 
change significantly. In comparison, a 10 
mg/kg dose of amphetamine led to an 
increase of 96% with respect to tryptophan. 
Similarly, serotonin and 5-
hydroxyindoleacetic acid levels remained 
unchanged.
 f
 
Vial et al.
93
 
-- Anorectic properties of 4-FA comparable to 
d-amphetamine (ED50 = 2.5 vs. 1.8 mg/kg)
 g
 
Beregi and Duhault
94
 
-- 4-FA administration (100 µmol/kg) failed 
to produce serotonin depletion in rat brain 
sections 3 days after administration. 
h
 
Harvey et al.
95
 
-- Intracerebroventricular injection of 4-FA 
(200 µg) resulted in increased levels of 
serum corticosterone, which pointed toward 
a mechanism without serotonin 
involvement since serotonergic neurotoxin 
administration did not impact on elevation. 
Dexamethasone pre-treatment (4 mg/kg) 4 
h before measurement prevented 
corticosterone elevation. 
i
 
McElroy et al.
96
 
Drug discrimination: 
j 
Rats trained to 
discriminate fenfluramine (3 mg/kg) and saline. 
4-FA (1.0–4.0 mg/kg) was found to substitute; 
100% lever selection at 4 mg/kg.  
-- McElroy and Feldman
72
 
-- Tissue distribution following 4-[
18
F]A 
administration (i.v.) in mice was detected 
after 5 min (% does/organ:  liver > kidneys 
> lungs > small intestines > brain > spleen) 
followed by a rapid decline at the 30 min 
and 60 min mark. 
k
 
Shiue et al.
97
 
Drug discrimination: 
l
 4-FA displayed (+)-
amphetamine-like discriminative stimulus 
effects; ED50: 0.23 mg/kg, 1.25 µmol/kg for 
training drug; 0.43 mg/kg, 2.11 µmol/kg for 4-
FA; no substitution observed for (+)-MBDB and 
MMAI. 
Microdialysis (rat striatum): 
l 
At 7 mg/kg 
(i.p.) of 4-FA, increase of extracellular DA 
levels (849%) 1 h after administration and 
non-significant decrease in DOPAC; when 
DA returned to baseline 3 h later, DOPAC 
and HVA concentrations still decreased. No 
effects of the 1.75 mg/kg dose. DA levels 
increases ~250% at 3.5 mg/kg (at 90 and 
120 min post-injection). (+)-Amphetamine 
(2.0 mg/kg, i.p.) significantly increased 
dialysate DA levels from 30 to 120 min. 
DOPAC concentration not altered but HVA 
significantly decreased in DA dialysates at 
1.5 h and 2 h following amphetamine 
injection. 
Marona-Lewicka  et al.
70
 
Self-administration:
 m
 In rhesus monkeys, 4-FA 
functioned as a positive reinforcer under fixed-
ratio (FR) 25 schedule (biphasic dose-response) 
and progressive-ratio (PR) conditions; 
reinforcing efficacy (PR schedule) lower than 
that of d-amphetamine. Potency (FR): 0.3 mg/kg; 
potency (PR): ED50 = 0.26 µmol/kg/injection; d-
-- Wee et al.
7
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amphetamine: ED50 = 0.04 µmol/kg/injection. 
Evaluation of anti-Parkinson effects: 
n 
4-FA 
reported to significantly reduce haloperidol-
induced catalepsy in rats. 
 
Conditioned place preference:
 n 
4-FA did not 
induce behaviour associated with drug 
dependence.  
 
-- Nagel and Schmidt
98, 99
 
-- Cortical EEG and EMG: 
o 
5 mg/kg (i.p.); 
wakefulness period: power spectral patterns 
revealed an increase in frequency range of 
7.0−8.5 Hz and a decrease in that of 
11.5−19.0 Hz for the first 7 h and decreased 
power spectra in the range 6.5−30.5 Hz for 
8 h during non-REM sleep. 4-FA led to 
increased wakefulness for 7 h after 
administration; REM and non-REM sleep 
not detected in 2 h to 6 h following 
administration. 
Uchiyama  et al.
100
 
Locomotor activity: 
p
 Dialysate DA correlated 
positively with ambulation and stereotypy 
whereas dialysate 5-HT correlated positively 
with stereotypy but not ambulation.  
Microdialysis (rat nucleus accumbens): 
p 
Intravenous administration of 4-FA led to 
dose-related increases in dialysate: DA ~ 
12-fold and 5-HT ~15-fold.   
Baumann et al.
71
 
a 
Ref 
4
: male Sprague-Dawley rats; female NMRI mice. 
b 
Ref 
79
: Anorexia test. Rats: dose at which food intake was reduced by 50% for 2 h when drug administered orally one hour 
previously; dogs: oral minimum dose delaying food ingestion for 2 h. Analgesia (Haffner’s method in mice): intraperitoneal 
dose which inhibits reflex of biting the artery clip placed on tail by 50%. Anticonvulsant action: oral dose, which protects 
50% of mice from tonic extension; bucco-occipital electroshocks were given (7.5 to 30 V lasting 1 s). Vasopressive action: 
blood pressure variation in pithed rat in mm Hg following intravenous administration. 
 
c 
Ref 
89
: Total radioactivity in the brain of male white Harlan rats was measured 20 min after i.p. injection of 5 μmol DL-5-
hydroxytryptophan-3-
14
C/kg.  
d 
Ref 
82
: male albino Wistar-derived rats; drugs administered intraperitoneally; drug levels in whole brain determined by 
methyl orange assay; tryptophan hydroxylase activity in whole brain homogenates assayed spectrofluorometrically; 
monoamine oxidase inhibition also determined, see Table 2. Serotonin and 5-hydroxyindoleacetic acid levels in whole brain 
assayed spectrofluorometrically following derivatization.  
e 
Ref 
92
: Sprague-Dawley rats; intraventricular injection (600 µg) with and without iprindole (10 mg/kg, i.p. one hour before 
drug administration) treatment; cerebellum was removed to dissect into brainstem and telencephalon-cortical sections.  
f 
Ref 
93
: female Wistar rats; brain levels of tryptophan, serotonin and 5-hydroxyindoleacetic acid were determined following 
sacrifice after 60 min (amphetamine) and 90 min (4-FA), respectively.  
g 
Ref 
94
: male Long-Evans rats; inhibition of food consumption determined 2 h after oral administration of test drug. Values 
expressed as percentage of food consumed the preceding day.   
h 
Ref 
95
: Male albino rats (i.p. drug administration); brain sections B-7, B- and B-9 were isolated three days following 
administration and stained to determine abnormal staining and extent of neurotoxicity.  
i 
Ref 
96
: Male albino rats; trunk blood collected one hour after injection (i.c.v.); dexamethasone treatment (inhibition of 
pituitary ACTH secretion): 4-FA given 1 h before rats were sacrificed (i.p.) and either after dexamethasone (1 mg/kg i.p.) or 
4 h after dexamethasone (4 mg/kg i.p.); chronic depletion of brain 5-HT induced by pre-treatment with p-
chlorophenylalanine or 5,7-dihydroxytryptamine.  
j 
Ref 
72
: male albino rats. 
k 
Ref 
97
: Female CF-1 mice; lateral tail vein injection (0.3-1.5 mCi); tissues removed after 5, 30 and 60 min.   
l 
Ref 
70
: Male Sprague-Dawley rats; trained with (+)-amphetamine (1 mg/kg, 5.4 µmol/kg (i.p.), (+)-MBDB (1.75 mg/kg, 
7.18 µmol/kg (i.p.), MMAI (1.71 mg/kg, µmol/kg (i.p.). Microdialysis: dialysate collected every 30 min (striatum); i.p. 
injections of 4-FA HCI at 1.75, 3.5, and 7.0 mg/kg followed by determination of dopamine, DOPAC, and HVA; dialysates 
collected 1.5 h before and extended 3 h after injection of 4-FA or (+)-amphetamine. 
m 
Ref 
7
: Seven male rhesus monkeys; FR schedule: baseline dose of cocaine = 0.03 mg/kg/injection; test drugs 0.003–1.0 
mg/kg; PR schedule: baseline dose of cocaine maintaining maximum injections = 0.1 or 0.3 mg/kg/injection; test drug 
available at doses of 0.003–1.0 mg/kg. For FR schedule, mean dose that maintained responding at the peak of the biphasic 
curve was calculated for potency. For PR schedule, ED50 dose of dose-response function obtained in individual monkey and 
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averaged across monkeys for mean.  
n 
Refs 
98, 99
: Sprague-Dawley rats; several fluorinated amphetamines and MDMA were included in these investigations. 1-
(3,4-Difluorophenyl)-N-ethylpropan-2-amine was chosen as a representative example and it was claimed that 4-FA, amongst 
others, gave similar results. Haloperidol (i.p.) was administered at 0.5 mg/kg; quantitative assessment of descent latencies (in 
seconds) included comparisons between haloperidol and test drug. Conditioned place preference: daily dose of test drug was 
5 mg/kg following FDA protocols; further details were not provided.   
o 
Ref 
100
: Male Sprague-Dawley rats (10 weeks old); electromyogram (EMG) and electroencephalogram (EEG) recorded for 
48 h (24 h after saline treatment and 24 h following i.p. drug administration of 5 mg/kg); Cortical EEG and EMG signals 
were amplified, filtered (EEG, 0.5−35 Hz; EMG, 16–128 Hz) and recorded using ‘SleepSign’ software.  
p 
Ref 
71
: Male Sprague-Dawley rats; microdialysis probe tips implanted in nucleus accumbens; locomotor activity: sensor 
ring lined with photobeams spaced 2.54 cm apart positioned in horizontal plane; activity monitored in 20 min bins, starting 
60 min before intravenous drug injections and continuing for 120 min; ambulation and stereotypy quantified separately; 
ambulation is defined as the total distance travelled in the horizontal plane (measured in cm); rats received intravenous 
injection of 1 mg/kg of drug at time 0, followed by 3 mg/kg at 60 min and dialysate samples were analysed for 5-HT and 
DA.  
 
B.  Routes of administration and dosage 
4-FA appears to be most commonly administered orally or by nasal insufflation (snorting) 
although the latter has also been associated with intense intranasal burning sensations and 
pain.
74, 101, 102
 A recent survey of 4-FA users in the Netherlands revealed a range of dosage 
levels that may be encountered: 50–100 mg (44 participants, 17.6%), 100–150 mg (105 
participants, 42.2%), more than 150 mg (48 participants, 19.2%, the remainder did not 
know).
74
 Some anecdotal reports indicate that higher doses might also be used.
101, 103
 
Examples can be found in the patent literature where 4-FA was captured as a potential 
ingredient in pharmaceutical formulations.
98, 99, 104, 105
    
 
C. Pharmacokinetics 
Information collected from systematic studies in humans is lacking. 4-FA has been 
identified as one of several metabolites formed in male Sprague-Dawley rat brain in 
following subcutaneous and intracerebral of para-fluoro-deprenyl.
25
 A transient, i.e. short-
lasting, reduction of serotonin levels was observed in male albino Wistar rat brain 
homogenates after administration of a 0.1 mmol/kg dose. Based on the analysis of drug 
concentration levels within the first four hours, a half-life of 3.7 h was calculated for 4-FA 
which compared to about 1 h in the case of amphetamine in the rat brain.
82
 Intravenous 
injection of 4-[
18
F]A into female CF-1 mice revealed that uptake into brain tissue was 
detected after 5 minutes (% does/organ:  liver > kidneys > lungs > small intestines > brain 
> spleen) followed by a rapid decline at the 30 min and 60 min mark.
97
 Duration of effects 
obtained from self-reports of 4-FA users: less than 4 hours (57 participants, 22.9%), 4–6 
hours (110 participants, 44.2%); 6–8 hours (54 participants, 21.7%) and more than 8 hours 
(28 participants, 11.2%).
74
 
5. Toxicology 
Oral administration (white female Cartworth mice): LD0 = 15 mg/kg, LD50 = 25 mg/kg, 
LD100 = 50 mg/kg.
1
 Intraperitoneal administration in mice: LD50 = 46.4 mg/kg
4, 106
 and 46 
mg/kg, respectively.
79
 Oral administration (male CD Servier mice): LD50 = 150 mg/kg 
(comparison to d-amphetamine under identical conditions: 120 mg/kg).
94
 A recently 
carried out cytolysis test that employed 4-FA did not lead to observations of cytotoxic 
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effects under the conditions studied (4 h incubation at 37°C, drug concentration 100 μM).78 
Data on the effects of 4-FA metabolites are not available.  
6. Adverse reactions in humans 
Tables 4 and 5 provide an overview of fatal and non-fatal intoxications obtained from the 
scientific literature and from reports received by EMCDDA. Case report data reported in 
the scientific literature that unambiguously confirm a causal relationship between adverse 
4-FA and presence in biofluids are limited to a relatively low number of cases. In cases 
where this information is available (e.g.
38
), sympathomimetic features, typically 
encountered with some amphetamine-type stimulants, have been observed. A recent study 
carried out in the Netherlands,
74
 which included a systematic survey of 4-FA users, who 
identified the main positive effect and the three most frequent adverse effects, confirmed 
that adverse effects of 4-FA were consistent psychomotor/entactogen stimulant profile 
(Table 6).  
 
 
Table 4. Fatal case reports associated with α-PVP published in scientific literature. 
Year Cases Patient/Age Context/clinically related 
comments  
Notes Ref 
2012 1 F/44 HIV-positive, 18 years history of 
drug dependence undergoing 
methadone treatment. Death 
considered due to high level of 
methadone in combination with 4-
FA and amphetamine. 
Whole blood analysis:  
4-FA 0.58 mg/kg; amphetamine 
0.30 mg/kg; diazepam 0.029 
mg/kg; oxazepam 0.043 mg/kg, 
methadone 0.65 mg/kg.  
Johansen et al.
33
 
2013 1 Not reported Not reported.  Detection of 4-FA in one post-
mortem blood sample. 
Rosano et al.
52
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Table 5. Non-fatal case reports associated with detection of 4-FA reported in the scientific literature.
a
 
Year Cases Patient/
Age 
Context/clinically related comments 
(examples) 
Notes Ref 
2012 14 12 x M, 
19-38; 
2 x F, 17 
and 21 
Case history details not reported. Amphetamine 
also detected in most cases; whole blood 0.049 
mg/kg – 0.70 mg/kg; in nine cases, additional 
drugs were detected, such as several 
benzodiazepines, tetrahydrocannabinol (THC), 
ketamine, 4-methylamphetamine and lidocaine.  
One rape case and 13 
DUID cases observed 
between 2009 – 2011. 
Whole 4-FA blood 
concentrations in 
DUID cases between 
0.006 – 0.43 mg/kg 
(mean 0.087 mg/kg, 
median 0.021 mg/kg).  
Johansen et al. 
33
 
2012 2 Not 
reported 
Case 1: police traffic check and medical 
examination indicative of sympathomimetic drug 
use: pupils dilated and delayed contraction in 
response to light; fingertips trembling; Romberg 
test showed tremor and swaying; restless 
behavior. Case 2: symptoms associated with 
psychostimulants, such as slow pupil light reflex, 
tremor and restlessness. 
DUID cases. 4-FA 
serum concentrations 
350 ng/mL and 475 
ng/mL.  
Röhrich et 
al.
38
 
2012 14 Not 
reported 
Not reported.  4-FA was detected in 
12 cases subjected to 
hair analysis. 
Rust et al.
39
 
2013 14 Not 
reported 
Not reported. Urine drug screening of authentic 
samples obtained from ‘addiction treatment 
clinics’ during one year in Sweden.  
In combination with 
4-FMC (3), 3-FMC 
(1) and MDPV (1). 
Total number of urine 
samples: 1335. 
Al-Saffar et 
al.
43
 
2013 2 Not 
reported 
Not reported. In 2010, 103 cases received from 
patients presenting at emergency departments 
across Sweden. 
4-FA detection 
reported in 2 cases. 
Helander et 
al.
45
 
2013 5 Not 
reported 
Not reported. Analysis of 1335 DUID cases. 4-FA detected in 
whole blood and 
considered below the 
legal limit.  
Pedersen et 
al.
48
 
2014 1 M, 18 Abrupt onset of nausea, vomiting, shortness of 
breath and chest tightness 5 h after drug 
consumption; received intramuscular naltrexone 
two days prior to admission as part of opioid 
addiction treatment program; fluoxetine and 
trazodone were also taken. ‘Reverse takotsubo 
cardiomyopathy’: cardiogenic shock developed 
requiring invasive management and life support. 
Acute cardiomyopathy caused by 4-FA 
catecholamine- induced myocarditis and/or small 
vessel myocardial ischemia was suggested. 
 
It has been suggested that the medication used 
during treatment might have contributed to 
triggering the Takotsubo syndrome.
107
 
4-FA urine and serum 
levels 64,000 ng/mL 
and 118 ng/mL. Also 
detected in urine: 
naproxen, fluoxetine, 
trazodone, 
naltrexone, nicotine, 
and cotinine in urine; 
in serum: 4-FA, 
naproxen, trazodone, 
and cotinine. 
Al-Abri et 
al.
56
 
2015 1 M, 27 Patient with history of polysubstance dependence; 
agitated with non-sensible speech, diaphoresis, 
dilated pupils, and hyperreflexia without clonus. 
Vital signs included: heart rate 156 beats/min and 
rectal temperature 41.4 °C; treatment: dextrose 
(50 g, i.v.), midazolam (multiple boluses, i.v., 28 
mg in total), and submerged in ice water.  
Urine tests with 
EMIT positive for 
amphetamines and 
PCP; qualitative 
serum and urine 
analysis confirmed 
presence of 4-FA. 
Laskowski et 
al.
66
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2015 1 M, 35 Routine traffic control; slow coordination, 
deficiency in concentration, washed-out 
pronunciation, agitation, restlessness, dry mouth, 
eyes reddened, and glassy, and pupil 
abnormalities (slow reaction to light, enlarged 
pupils). Orders had to be repeated multiple times 
and the man could not follow long sentences.  
Blood sample taken 1 
h and 55 min 
afterwards: THC 0.9 
ng/mL; 11-OH-THC 
< 0.8 ng/mL; THC-
COOH 6.8 ng/mL; 4-
FA 90.0 ng mL. 
Maas et al.
67
 
2015 1 Not 
reported 
Details not reported.  4-FA detected in one out of 
34 irregular attendees of drug treatment centre.   
4-FA detected.  Sundström et 
al.
69
 
2015 4 Not 
reported 
Tachycardia, headache, dizziness, restlessness, 
visual disturbances, tremors, agitation, tachypnea, 
confusion, nausea, vomiting, abdominal pain, 
dysphagia, neck pain, feeling of fainting. 
Reported to the 
Dutch Poisons 
Information Centre in 
2013. 
Hondebrink et 
al.
64
 
a 
The EMCDDA also received reports about positive identifications of 4-FA in biofluids although case level data are not 
reported, see Table 7. 
 
 
Table 6. Reported positive and adverse effects of 4-FA, adapted from Linsen et al.
a,74
  
Effects n % 95% CI 
Positive 
Stimulatory 145 58.2 51.4–64.3 
Euphoria 69 27.9 22.1–33.3 
Empathic 24 9.6 6.0–13.3 
Sedative 11 4.3 1.1–5.6 
Adverse 
Difficulty falling asleep 133 53.4 47.4–59.0 
Dry mouth 109 43.8 37.4–50.2 
Jaw tension/cramp 106 42.6 36.2–49.0 
Elevated heartbeat 92 36.9 30.9–43.4 
Sweating/high body temperature 83 33.3 27.7–39.4 
Lowered mood in the days after use 49 19.7 14.9–24.5 
Muscle weakness in days after use 46 18.5 13.7–23.3 
Nausea 17 4.8 3.6–10.0 
The drug had no effect 16 6.4 3.6–9.6 
Tachycardia 29 11.6 8.0–15.7 
Headache 21 8.4 5.2–12.4 
Loss of memory (while intoxicated) 17 6.8 4.0–10.4 
Unpleasant hallucinations 3 1.2 0.0–2.8 
Difficulty breathing 2 0.8 0.0–2.0 
Tolerance (higher dose needed after first use) 16 6.4 3.6–9.6 
Other 6 2.4 1.0–4.6 
a
 Multiple answers were possible for adverse effects; CI = confidence interval. Users of 4-FA have identified pro-social 
effects similar to MDMA, which was not associated with effects induced by amphetamine.   
 
7. Dependence potential 
A. Animal Studies 
As shown in Table 3, self-administration studies in rhesus monkeys indicated that 
4-FA functioned as a positive reinforcer under fixed-ratio (FR) 25 schedule 
(biphasic dose-response) and progressive-ratio (PR) conditions. The reinforcing 
efficacy (PR schedule) was lower than that of d-amphetamine and it was 
hypothesized that the 5-HT releasing effects of 4-FA might have negatively 
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impacted on the potency as a reinforcer compared to d-amphetamine. 
Correspondingly, it was suggested that a DA/5-HT ratio might serve as a potential 
predictor. Taking into account the EC50 values obtained from rat brain synaptosome 
release assays, the DA/5-HT ratio obtained for 4-FA was 0.05 compared to 0.004 
for d-amphetamine, which reflected the higher 5-HT releasing potency of 4-FA.
7
 
An example was found in the patent literature where it was claimed that 4-FA did 
not display signs of dependence potential based on experiments that assessed 
conditioned place preference (Sprague-Dawley rats).
98, 99
 Further work seems 
warranted to determine the extend of dependence potential in animals.  
B. Human Studies 
Data from clinical studies in humans are not available.  
8. Abuse potential 
A. Animal Studies 
As shown in Table 3 and Section 4A, limited information is available. From the 
available data it appears that 4-FA shows classic features associated with 
psychomotor stimulants such as amphetamine. Further studies seem warranted to 
clarify the similarities and differences that exist between 4-FA and amphetamine 
and other amphetamine-type substances. 
B. Human Studies 
Data from clinical studies in humans are not available.  
9. Therapeutic applications and extent of therapeutic use and epidemiology 
of medical use 
Not applicable. 
 
10. Listing on the WHO Model List of Essential Medicines 
4-FA is not listed. 
11. Marketing authorizations (as a medicinal product) 
4-FA was never marketed as a medicinal product.   
12. Industrial use 
4-FA has no recorded industrial use. 
13. Non-medical use, abuse and dependence  
 
Use of 4-FA appears to be limited to recreational substance users rather than the general 
population. The mode of use may involve the combinational use (intentionally or 
unintentionally) of other drugs and users may be unaware of the exact dose or compound 
being ingested (by whatever route). Dependence-producing properties in humans have not 
been studied. The appearance of 4-FA in Europe has been observed since at least 2007. 
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Over the years, it has been found in products sold as ‘ecstasy’/MDMA tablets, 
amphetamine powder but also as adulterants present in other illicit controlled substances.
64, 
73, 74, 102, 108-110
  
14. Nature and magnitude of public health problems related to misuse, abuse 
and dependence 
Surveys that systematically assess the prevalence of use 4-FA within the general 
population are not available. Research carried out in the Netherlands suggest that 4-FA, 
which originally appeared as one of many new psychoactive substances (NPS) (e.g. as an 
adulterant or as an alternative to reduced availability of substances such as MDMA) has 
established itself as a substance of choice in a subpopulation of recreational substance 
users, especially those who might prefer using this substance in a social context.
64, 74
 
However, further studies seem indicated to investigate the prevalence of use in more detail. 
15. Licit production, consumption and international trade 
In countries where 4-FA is not subject to legislative control, marketing efforts might 
include advertisement and sale as a ‘research chemical’. Information about agricultural, 
cosmetic or industrial use of 4-FA is not available. 
16. Illicit manufacture and traffic and related information 
Information provided to Europol and EMCDDA by European Member States, Turkey and 
Norway is summarized in Table 7.  
 
Table 7. Information available on the EMCDDA’s European database on new drugs (EDND). The European Union Early 
Warning System, the Reitox National Focal Points in the EU Member States, Turkey and Norway, as well as the Europol 
National Units and their networks, provided data. 
a
 
Information provided to EMCDDA 
Seizures 2008: 
 Belgium – 2 seizures of powder. 
 Denmark – 2 seizures; 1 sample seized (4 g) containing 1% amphetamine. 
 Netherlands – 4 collected samples of powder; 1 collected sample of capsule; 1 collected sample of liquid; 3 
seizures totalizing 212 g of powder and 1 seizure of liquid containing also 2C-B and BZP. 
Seizures 2009 (January – June) plus update from 9th Annual EWS meeting, 4-5 June 2009, Lisbon (A. Gallegos and R. 
Sedefov): 
 Austria – 2 seizures of powder totaling 707 g and 4 collected samples of powder. 
 Belgium – 6 seizures of 33.9 g powder; 1 seizure of 49.79 g of paste/sticky powder and 1 seizure of tablets. 
 Croatia: 4 seizure of white powder also containing amphetamine traces, caffeine, mannitol and creatine. 
 Denmark – 5 seizures; one seizure of 4 g white powder that also contained 1% amphetamine. 
 Estonia – 1 seizure of 0.32 g powder. 
 Finland – 1 seizure of 12 tablets (Forensic Laboratory) and 2 seizures of powder/capsule, 5g/3units (Customs) 
 France – 8 seizures of powder, 3115 g 
 Germany – seizure between November 2008 and June 2009: in one case, 60 kg of amphetamine were seized, 14 
of which were a mixture of amphetamine and 4-FA; two seizures of a ‘few grams’ of powder and one seizure of 1 
kg.    
 Hungary – 2 seizures of powder, 2.5 g (powder in 36 capsules); 1 collected sample of 638.2 g powder; 4 seizures 
of 211 tablets (from 2008), one seizure of 700 g homogenous powder. 
 Netherlands – From DIMS: 60 collected samples of powder, 6 collected samples of tablets and 1 collected sample 
of liquid; from NFI: 1 seizure of powder > 340 kg; 98 seizures of powder, > 100 kg, 98 seizures of powder > 100 
kg in combination with amphetamine. 
 Slovakia – 1 seizure of 16 mg powder. 
 Sweden – 105 seizures of 6174 g powder; 7 seizures of 21 mL liquid; 24 biological samples of urine; 71 
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biological samples of blood and 57 seizures of 1460.4 g powder. 
 United Kingdom – 2 seizures of 0.9 mL liquid; 102 seizures (93 kg powder); 4 seizures (6.67 kg powder); 6 
seizures of paste (6.355 kg); 1 seizure of 300 g powder; 1 seizure of 7.627 kg paste containing also amphetamine. 
UK National Focal Point also reported a seizure of 371 mg of a pale pink powder in Guernsey.  
Seizures 2010: 
 Belgium – 1 seizure of 112.5 tablets containing also caffeine and piperonal; 1 seizure of 3.18 g powder 
containing also caffeine and amphetamine; 3 biological samples of urine. 
 Denmark – 13 seizures. 
 Finland – 3 seizures of 5g powder; 1 biological sample of blood; 13 seizures of 46 g powder and 1 seizure of 2 
tablets (last two, both reported as 3-FA or 4-FA). 
 France – 4 seizures of 340 g liquid; 7 seizures of tablets. 
 Hungary –10 seizures of 35 g powder and 7 seizures of 14 tablets (reported as fluoramphetamine). 
 Netherlands – 13 seizures: 2775 tablets and 65 g powder (from NFI). 
 Norway – 8 seizures of 106 g powder. 
 Poland – 1 seizure of 10 capsules; 1 seizure of 550 tablets containing piperonal and caffeine. 
 Slovenia – 5 seizures of 9.21 g white powder, most of the samples containing caffeine. 
 United Kingdom – From a variety of forensic providers. Key Forensics: 3 seizures of powder, 157.7 g; 1 seizure 
of powder, 23.5 g in an amphetamine sample. From LGC Forensics: 6 seizures of powder, 136.3 g; 13 seizures of 
powder, 520 g. From FSNI: 1 seizure of 16.76 g powder containing traces of mephedrone; 1 seizure of 102 g 
white powder. From FSS: 3 seizures of liquid, 1.6 mL; 152 seizures of powder, 46.4 kg; 1 seizure of 5 tablets. 
From Scotland: 9 seizures of powder, 529.5 g.From Key Scientifics: 3 seizures of powder, 14.46 g; 1 seizure of 2 
tablets, 0.46 g; 3 seizures of powder, 5.73 g. 
Seizures 2011: 
 Austria –1 seizure of 9.4 g of powder. 
 Bulgaria – 3 seizures of 5.60 g of powder 
 Denmark – 5 (19)* seizures of 442.2 g of powder (*The number in brackets is the total number of individual 
exhibits in all seizures). 
 Finland – 38 seizures of 198 g of powder; 4 seizures of 20 tablets/blotters; 7 seizures of 82 g of powder; 2 
biological samples of blood (all reported as 2-, 3- or 4-FA). 
 France – 17 seizures of tablets. 
 Hungary – 18 seizures of 15 g of powder, 60 seizures of 3235 tablets; 27 seizures of 26 g powder also containing 
amphetamine; 1 seizure of 3 tablets also containing 2C-D; 462 biological samples. 
 Italy – 1 seizure of 1.18 g of tablets; 2 seizures of powder (one seizure also contained MDPV, 4-MEC, lidocaine 
or procaine and the other also contained mephedrone and MDPV, lidocaine and propanamide were also 
identified). 
 Netherlands – 7 seizures of 279 tablets and 16 g powder (from NFI); 61 collected samples of powder (from 
DIMS); 9 collected samples of tablets (from DIMS); 3 collected samples of liquid (from DIMS); 1 collected 
sample of capsules (from DIMS). 
 Norway – 3 seizures of 517 g of powder. 
 Spain – 1 seizure of powder. 
 United Kingdom – From FSNI: 1 seizure of 2.05g of powder; from FSS: 13 seizures of 400.1 g powder. 
Seizures 2012: 
 Austria – 1 seized powder sample. 
 Belgium – 1 kg white powder seized by customs at airport, package sent from China. 
 Denmark – 3 cases of seized powder, 9.5 g. 
 Spain – Seizure of 7760 tablets and 15 tablets where 4-FA was present in combination with other substances; 
seizure of 210 g powder. 
 Finland – Customs seizures of 243.8 g powder (53 cases), 18 tablets/blotter and 28.8 g ‘other’. Police seizure of 
28 g powder and 10 cases of biological analyses with positive identification. Note: not clear what positional 
isomer might have been identified.  
 France – seizures of tablets (5 cases) and two liquids (customs); police seizure of 100 tablets. 
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 Hungary – seizures of 421 tablets (13 cases), 2 g powder (2 cases); presence of additional substances: 7 g of 
powder (4-FA + amphetamine, 4 cases), 38 g of powder (4-FA + MDPV, 1 case), 33 tablets (4-FA + 
methoxetamine, 1 case), 30 tablets (4-FA + 4-MEC + methylone, 1 case); 43 samples of biological origin tested 
positive for 4-FA but details not reported.   
 Netherlands – seizure of 1060.2 g (27 cases), 7 tablets and 11 tablets (4-FA + PMMA + 3,4-
dimethoxymethamphetamine).    
 Norway – seizure of materials in three cases and positive identification in one biofluids sample. 
 Poland: 1 g powder and 2.99 g powder also containing amphetamine and caffeine.   
 Slovakia – seizure of 367 g powder (see also Reitox National Focal Point Slovakia, below). 
 Slovenia – 1 powdered sample (1.3 g). 
 United Kingdom – Seizures of 1010 g powder (18 cases), 1488.57 mL liquid (3 cases), 1 tablet and 1 ‘other’ 
(6.34 g). 
Seizures 2013: 
 Denmark – 2 cases of collected powder (1.9 g) 
 Finland – Powder (141.6 g, 34 cases); positional isomer not specified. 
 France – seizure of tablets (6378 g, 37 cases), liquid (9312 g, 40 cases), and 97 g powder (8 cases).  
 Greece – seizure of 2.4 g powder 
 Italy – seizure of 1.69 g powder containing 4-FA + 4-MEC + methedrone (bk-PMMA) + methylone + 5-MeO-
MIPT + 5-MeO-DALT. 
 Latvia – seizure of 49.42 g powder 
 Poland – seizure of 796.66 g powder (64 cases) 
 Spain – 50 g powder (12 cases) and 11 g powder (18 cases) containing additional substances. 
Information provided to Europol 
Seizures 2009 (January – June) plus update from 9th Annual EWS meeting, 4-5 June 2009, Lisbon (A. Gallegos and R. 
Sedefov) and newsletter related to Europol’s SYNERGY project111  
 Sweden: Two seizures of 700 g and 340 g.  
 Netherlands: found at two illegal amphetamine laboratories. 
 From SYNERGY newsletter: ‘A total of 19 member states had replied to Europol’s request for information, with 
four member states (Finland, Germany, the Netherlands and the United Kingdom) reporting seizures of the 
substance, both in powder and tablet form. Additionally, insofar not yet officially provided, the Slovak Republic 
has also forensically identified this substance amongst submitted seizures. Equally, reports submitted to the 
EMCDDA from the NFP’s reveal that seizures of this substance have taken place in Belgium, Croatia, Denmark, 
Estonia, France and Hungary.’ 
 
‘In fact, the Dutch National Crime Squad reported that this substance was increasingly emerging on the national 
users market. Also, two production sites had been dismantled, with one in January 2009 where both this 
substance and its precursor chemical were seized; the other took place in February 2009, where traces of both this 
substance and amphetamine were found. Besides, one additional seizure totalling 169 kg of the substance was 
made in January 2009.’  
Reitox National Focal Point Slovakia 
 Rented premises were used for 4-FA manufacturing, packing and distribution. Mixing equipment and facilities 
for pills processing were encountered, including 367 g powdered 4-FA. 
a
 Some of the data reported to Europol and EMCDDA may overlap. Data were drawn from bi-annual data gathering (EU 
EWS progress and final reports) and from individual Reporting forms submitted on an ad hoc basis to EMCCDA. Positive 
identifications of 4-FA in various biofluids have also been reported but further are not available. 
 
17. Current international controls and their impact 
Not applicable in terms of medical use. 
 
18. Current and past national controls 
The EMCDDA’s European database on new drugs (EDND) lists that the following 
countries have taken legislative measures to control 4-FA: Belgium, Czech Republic, 
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Denmark, Finland, France, Germany, Hungary, Italy, Latvia, Lithuania, Norway, Poland, 
Portugal, Slovakia, Slovenia, Sweden, Turkey, United Kingdom. 4-FA is not a controlled 
Substance in Greece. Confirmation from all Reitox National Focal Points, however, might 
be needed to obtain an update.   
19. Other medical and scientific matters relevant for a recommendation on 
the scheduling of the substance 
 
Not applicable. 
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42. Sulzer P, Jürschik S, Agarwal B, Kassebacher T, Hartungen E, Edtbauer A et al. Designer 
drugs and trace explosives detection with the help of very recent advancements in proton-transfer-
reaction mass spectrometry (PTR-MS). In: Aschenbruck N, Martini P, Meier M, Tölle J, editors. 
Future Security 7th Security Research Conference, Future Security 2012, Bonn, Germany, 
September 4-6, 2012. Heidelberg: Springer; 2012. p. 366-75. 
 
43. Al-Saffar Y, Stephanson NN, Beck O. Multicomponent LC-MS/MS screening method for 
detection of new psychoactive drugs, legal highs, in urine-Experience from the Swedish 
population. J Chromatogr B Analyt Technol Biomed Life Sci 2013;930:112-20. 
doi:10.1016/j.jchromb.2013.04.043 PMID:23727875 
 
44. Chen K-F, Lee H, Liu J-T, Lee H-A, Lin C-H. A microwave-assisted fluorescent labeling 
method for the separation and detection of amphetamine-like designer drugs by capillary 
electrophoresis. Forensic Sci Int 2013;228:95-9. doi:10.1016/j.forsciint.2013.02.045 
PMID:23597745 
 
45. Helander A, Beck O, Hägerkvist R, Hultén P. Identification of novel psychoactive drug use in 
Sweden based on laboratory analysis - initial experiences from the STRIDA project. Scand J Clin 
Lab Invest 2013;73:400-6. doi:10.3109/00365513.2013.793817 PMID:23692208 
 
46. Mwenesongole EM, Gautam L, Hall SW, Waterhouse JW, Cole MD. Simultaneous detection 
of controlled substances in waste water. Anal Methods 2013;5:3248-54. doi:10.1039/c3ay40655e  
 
47. Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K et al. 
Differentiation of regioisomeric fluoroamphetamine analogs by gas chromatography-mass 
37
th
 ECDD (2015) Agenda item 5.4  4-Fluoroamphetamine 
 
 
 Page 30 of 35 
spectrometry and liquid chromatography-tandem mass spectrometry. Forensic Toxicol 
2013;31:241-50. doi:10.1007/s11419-013-0184-7  
 
48. Pedersen AJ, Dalsgaard PW, Rode AJ, Rasmussen BS, Mueller IB, Johansen SS et al. 
Screening for illicit and medicinal drugs in whole blood using fully automated SPE and ultra-high-
performance liquid chromatography with TOF-MS with data-independent acquisition. J Sep Sci 
2013;36:2081-9. doi:10.1002/jssc.201200921 PMID:23610028 
 
49. Petrie M, Lynch KL, Ekins S, Chang JS, Goetz RJ, Wu AHB et al. Cross-reactivity studies and 
predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine 
screening immunoassays. Clin Toxicol 2013;51:83-91. doi:10.3109/15563650.2013.768344 
PMID:23387345 
 
50. Philp M, Shimmon R, Stojanovska N, Tahtouh M, Fu S. Development and validation of a 
presumptive colour spot test method for the detection of piperazine analogues in seized illicit 
materials. Anal Methods 2013;5:5402-10. doi:10.1039/c3ay40511g  
 
51. Roman M, Ström L, Tell H, Josefsson M. Liquid chromatography/time-of-flight mass 
spectrometry analysis of postmortem blood samples for targeted toxicological screening. Anal 
Bioanal Chem 2013;405:4107-25. doi:10.1007/s00216-013-6798-0 PMID:23455644 
 
52. Rosano TG, Wood M, Ihenetu K, Swift TA. Drug screening in medical examiner casework by 
high-resolution mass spectrometry (UPLC-MSE-TOF). J Anal Toxicol 2013;37:580-93. 
doi:10.1093/jat/bkt071 PMID:23999055 
 
53. Rosenauer R, Luf A, Holy M, Freissmuth M, Schmid R, Sitte HH. A combined approach using 
transporter-flux assays and mass spectrometry to examine psychostimulant street drugs of 
unknown content. ACS Chem Neurosci 2013;4:182-90. doi:10.1021/cn3001763 PMID:23336057 
 
54. Zuba D, Byrska B. Prevalence and co-existence of active components of 'legal highs'. Drug 
Test Anal 2013;5:420-9. doi:10.1002/dta.1365 PMID:22549997 
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